Categories Other Industries

Rite Aid narrows earnings outlooks ahead of Albertsons vote

Shares of the drug retailer Rite Aid Corp (RAD) tanked on Monday after the company narrowed its fiscal 2019 earnings outlook. The company now expects its adjusted loss per share to be between four cents and break-even, compared to the earlier projected EPS of $0.02 – 0.06 issued on April 12, 2018.

Shares were down 12.5% before the opening bell.

Meanwhile, Rite Aid expects the outlook for sales and same-store sales to remain unchanged as prescription count growth and pharmacy reimbursement rates are predicted to be in line with estimates. Sales are expected to be between $21.7 billion and $22.1 billion, and same-store sales in the range of flat to up 1%.

Rite Aid, which is close to completing its merger with grocery retailer Albertsons Cos., blamed the generic drug pricing for this updated outlook. The company said the generic drug purchasing efficiencies are expected approximately $80 million below its previous experience and will not meet the expectations for the year.

RELATED: Rite Aid swings to profit in Q1  

Rite Aid/Albertsons merger

The special stockholders meeting scheduled for August 9 will vote on a proposal to approve its $24 billion mergers with the private firm Albertsons, which has received objection from a few investors. Now that Rite Aid has narrowed its profit outlook, the deal could be in jeopardy as Albertson is already under massive profit pressure.

If the proposed merger gets an approval, Rite Aid would then be a wholly owned subsidiary of Albertsons Companies Inc… The merged companies will be called  Albertsons Companies and will trade on the NYSE under the symbol “ACI”.

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top